Defining the HER2-low expressing subgroup of breast tumors enables both triple-negative breast cancers and hormone receptor-positive to benefit from T-DXd, signaling potential major advances in future treatment algorithms. The gene discussed is NR4A1; the disease is triple-negative breast carcinoma.